Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Research across Cancer
Related studies from across the Cancer family.
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule
A rare ovarian tumor diagnosis explained in a single patient case
This source is a case report review describing a 27-year-old female patient with an ovarian borderline mucinous tumor and carcinosarcomatous…
Doctors treated a 27-year-old woman with a rare ovarian tumor using fertility-sparing surgery and chemotherapy, with no signs of the cancer …
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center
Lockdowns Didn't Hurt Ovarian Cancer Survival
This retrospective cohort study of 218 patients at Bern University Hospital found primary ovarian cancer diagnoses decreased in 2020 and 202…
When the world shut down in 2020, hospitals faced a scary reality.
Residual disease after surgery linked to survival in low-grade serous ovarian cancer
For This Ovarian Cancer, Surgery Is Everything—Chemo May Not Help
This observational retrospective study of 25 patients with low-grade serous ovarian cancer found that residual disease status after primary …
For a rare ovarian cancer, a new study suggests that the quality of surgery is the single most important factor for survival, challenging th…
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study
Two Tiny Signals Could Help Doctors Tell Apart Two Ovarian Cancers
A cohort study analyzed transcriptome data from 68 patients with high-grade and low-grade serous ovarian carcinoma.
Two tiny gene signals may help doctors distinguish between two ovarian cancer types when biopsy results are unclear, guiding the right treat…
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Retrospective cohort study of 217 surgically treated borderline ovarian tumors in Southern Sweden compares conservative versus complete staging surgery
A Gentler Surgery for Ovarian Tumors May Be Safer Than We Thought
This retrospective, population-based cohort review evaluated 217 patients with borderline ovarian tumors (BOT) in Southern Sweden.
A less invasive surgery for borderline ovarian tumors may be just as safe as the standard approach, offering fewer complications without har…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
FDA approves a new treatment for advanced prostate cancer called Pluvicto
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds
Chemotherapy linked to immune system changes in ovarian cancer patients
An observational cohort study of 107 HGSOC patients and 50 healthy controls found chemotherapy was associated with modulation of NK cell rec…
Chemotherapy in ovarian cancer may restore natural killer cell markers to healthy levels and boost proteins that help immune cells fight tum…